Q2 Earnings Forecast for Biofrontera Issued By Roth Capital

Biofrontera Inc. (NASDAQ:BFRI) – Investment analysts at Roth Capital issued their Q2 2025 earnings per share estimates for shares of Biofrontera in a research note issued on Thursday, November 14th. Roth Capital analyst J. Aschoff anticipates that the company will post earnings of ($0.32) per share for the quarter. The consensus estimate for Biofrontera’s current full-year earnings is ($3.11) per share. Roth Capital also issued estimates for Biofrontera’s Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at $0.12 EPS, FY2026 earnings at $0.03 EPS, FY2027 earnings at $0.34 EPS and FY2028 earnings at $0.63 EPS.

Separately, Benchmark reissued a “buy” rating and issued a $7.00 target price on shares of Biofrontera in a research note on Friday.

Biofrontera Stock Down 8.4 %

Shares of BFRI stock opened at $0.67 on Monday. Biofrontera has a fifty-two week low of $0.61 and a fifty-two week high of $4.04. The firm’s 50 day moving average price is $1.02 and its two-hundred day moving average price is $1.08. The stock has a market cap of $3.72 million, a price-to-earnings ratio of -0.30 and a beta of 0.50.

About Biofrontera

Biofrontera Inc, a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection.